Azacitidine
Other / unclassified targets DNMT1, DNMT3A via inhibition
Regulatory milestones approvals, filings & regulatory actions · 6 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansion | US (FDA) | ONUREG | — | 2026-04-09 | fda.gov ↗ |
| Label expansions (3) | US (FDA) | VIDAZA | — | 2007-01-26 – 2022-05-20 | fda.gov ↗ |
| Approved | EU (EMA) | Vidaza | — | 2008-12-17 | europa.eu ↗ |
| Approved | US (FDA) | VIDAZA | — | 2004-05-19 | fda.gov ↗ |
Trials 615 · started per year
Also used as a comparator or background therapy in 197 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT07071155 Background | Mar 2026 → Mar 2028 expected | chronic myelomonocytic leukemia, chronic neutrophilic leukemia, myelodysplastic syndrome | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | Recruiting | No outcome recorded |
| Phase 157 trials | ||||||
| Phase 1 | NCT07439211 Background | Jul 2026 → Feb 2028 expected | acute myeloid leukemia | Jacqueline Garcia, MD | Not yet recruiting | No outcome recorded |
| Phase 1 | NCT07177079 Background | Mar 2026 → Dec 2028 expected | acute myeloid leukemia | Kittika Poonsombudlert | Recruiting | No outcome recorded |
| Phase 1 | NCT07320235 Comparator | Jan 2026 → Jun 2030 expected | acute myeloid leukemia | Douglas Tremblay | Recruiting | No outcome recorded |
| Phase 1 | NCT07014462 Background | Sep 2025 → Jun 2029 expected | acute myeloid leukemia | University of Vermont | Enrolling by invitation | No outcome recorded |
| Phase 1 | NCT06763341 Background | Jul 2025 → Jan 2027 | acute myeloid leukemia | City of Hope Medical Center | Suspended | No outcome recorded |
| Phase 1 | NCT06651229 Background | Mar 2025 → Aug 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Recruiting | No outcome recorded |
| Phase 1 | NCT06616636 Background | Jan 2025 → Aug 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06502145 Background | Jan 2025 → Dec 2026 expected | myelodysplastic syndrome | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 1 | NCT06397027 Background | Dec 2024 → Dec 2028 expected | refractory hematologic cancer | M.D. Anderson Cancer Center | Recruiting | No outcome recorded |
| Phase 1 | NCT06656494 Background | Dec 2024 → Jun 2027 expected | acute myeloid leukemia, myelodysplastic syndrome | Beijing InnoCare Pharma Tech Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1 | NCT06634394 Background | Oct 2024 → Oct 2027 expected | acute myeloid leukemia | Aptevo Therapeutics | Recruiting | No outcome recorded |
| Phase 1 | NCT06429449 Background | Jul 2024 → Dec 2026 expected | acute myeloid leukemia, monocytic leukemia | University of Colorado, Denver | Recruiting | No outcome recorded |
| Phase 1 | NCT06372717 Background | Jun 2024 → Mar 2027 expected | acute myeloid leukemia, myelodysplastic syndrome with excess blasts | Apollo Therapeutics Ltd | Recruiting | No outcome recorded |
| Phase 1 | NCT06008405 Background | Sep 2023 → May 2025 | acute myeloid leukemia, myelodysplastic syndrome | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05735184 Background | Jul 2023 → Apr 2030 expected | acute myeloid leukemia with mutated NPM1, acute myeloid leukemia, MLL gene rearrangement, myeloid sarcoma | Kura Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT05970822 Background | Jun 2023 → Mar 2025 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Biocity Biopharmaceutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05317403 Background | Mar 2023 → Jan 2027 expected | acute myeloid leukemia | Medical College of Wisconsin | Recruiting | No outcome recorded |
| Phase 1 | NCT05292664 Background | Mar 2023 → Jul 2028 expected | acute leukemia of ambiguous lineage, acute lymphoblastic leukemia, lymphoblastic lymphoma, myelodysplastic syndrome +1 | Andrew E. Place, MD | Recruiting | No outcome recorded |
| Phase 1 | NCT05829226 Background | Dec 2022 → Dec 2025 | acute myeloid leukemia, myelodysplastic syndrome | PureTech | Completed | No outcome recorded |
| Phase 1 | NCT05155709 Background | May 2022 → Apr 2024 | acute myeloid leukemia | Novartis Pharmaceuticals | Completed | No outcome recorded |
| Phase 1 | NCT05001828 Background | Apr 2022 → May 2026 overdue | acute myeloid leukemia | Polaris Group | Active not recruiting | No outcome recorded |
| Phase 1 | NCT05107856 Background | Mar 2022 → Jan 2024 | acute myeloid leukemia, chronic lymphocytic leukemia/small lymphocytic lymphoma, chronic myelomonocytic leukemia, follicular lymphoma +3 | Prelude Therapeutics | Terminated | No outcome recorded |
| Phase 1 | NCT05168202 Background | Jan 2022 → Jul 2024 | acute myeloid leukemia, myelodysplastic syndrome | Bristol-Myers Squibb | Terminated | No outcome recorded |
| Phase 1 | NCT04937166 Background | Jan 2022 → Apr 2025 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Kahr Medical | Terminated | No outcome recorded |
| Phase 1 | NCT04748848 Background | Oct 2021 → Mar 2022 | myeloid leukemia | Celgene Corporation | Terminated | No outcome recorded |
| Phase 1 | NCT04755244 Background | May 2021 → May 2023 | acute myeloid leukemia | ALX Oncology Inc. | Terminated | No outcome recorded |
| Phase 1 | NCT05048498 Comparator | Apr 2021 → Feb 2022 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Nanexa AB | Completed | No outcome recorded |
| Phase 1 | NCT04485065 Background | Sep 2020 → Dec 2023 | myelodysplastic syndrome | Innovent Biologics (Suzhou) Co. Ltd. | Suspended | No outcome recorded |
| Phase 1 | NCT04139434 Background | Jul 2020 → Dec 2025 | acute lymphoblastic leukemia, acute myeloid leukemia, chronic myelomonocytic leukemia | Newave Pharmaceutical Inc | Completed | No outcome recorded |
| Phase 1 | NCT04275518 Background | Jul 2020 → Dec 2025 overdue | acute myeloid leukemia, myelodysplastic syndrome | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 1 | NCT04241549 Background | Mar 2020 → Jul 2021 | acute myeloid leukemia | OncoVerity, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT04022785 Background | Sep 2019 → Oct 2022 | acute myeloid leukemia, myelodysplastic syndrome, myelodysplastic/myeloproliferative neoplasm | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 1 | NCT03814005 Background | Jul 2019 → Mar 2021 | acute myeloid leukemia, chronic myelomonocytic leukemia, impaired renal function disease, liver disorder +1 | Takeda | Completed | No outcome recorded |
| Phase 1 | NCT03813147 Background | May 2019 → Sep 2021 | acute myeloid leukemia, myelodysplastic syndrome | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT03843528 Background | May 2019 → Jul 2027 expected | juvenile myelomonocytic leukemia, mixed phenotype acute leukemia, myelodysplastic syndrome | Johns Hopkins All Children's Hospital | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03612739 Background | Dec 2018 → May 2019 | acute myeloid leukemia, myelodysplastic syndrome | Celyad Oncology SA | Withdrawn | No outcome recorded |
| Phase 1 | NCT03513484 Background | Nov 2018 → Dec 2023 overdue | acute myeloid leukemia, FLT3 internal tandem duplication | Northwestern University | Active not recruiting | No outcome recorded |
| Phase 1 | NCT03483948 Background | Oct 2018 → Sep 2019 | acute myeloid leukemia | Hutchison Medipharma Limited | Terminated | No outcome recorded |
| Phase 1 | NCT03326310 Background | Sep 2018 → Sep 2027 expected | chronic myeloid leukemia, myelofibrosis | University of Chicago | Recruiting | No outcome recorded |
| Phase 1 | NCT03298516 Background | Nov 2017 → Jul 2019 | acute myeloid leukemia | Genentech, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT03236857 Background | Nov 2017 → Apr 2023 | acute lymphoblastic leukemia, acute myeloid leukemia, neuroblastoma | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT03113643 Background | Jun 2017 → Sep 2021 overdue | CD4+/CD56+ hematodermic neoplasm, acute myeloid leukemia, myelodysplastic syndrome | Dana-Farber Cancer Institute | Recruiting | No outcome recorded |
| Phase 1 | NCT02954653 Comparator | Nov 2016 → Dec 2017 | acute myeloid leukemia | Pfizer | Terminated | No outcome recorded |
| Phase 1 | NCT02675452 Background | Jun 2016 → May 2024 | acute myeloid leukemia, refractory plasma cell neoplasm | Amgen | Terminated | No outcome recorded |
| Phase 1 | NCT02553941 Background | May 2016 → May 2019 | chronic myelomonocytic leukemia, refractory anemia with excess blasts in transformation | Brian Jonas | Completed | No outcome recorded |
| Phase 1 | NCT02721875 Background | Apr → Jun 2016 | myelodysplastic syndrome | Boehringer Ingelheim | Terminated | No outcome recorded |
| Phase 1 | NCT02750995 Background | Apr 2016 → Jan 2018 | acute myeloid leukemia, myelodysplastic syndrome | Daniel El Fassi | Completed | No outcome recorded |
| Phase 1 | NCT02783547 Background | Dec 2015 → Jun 2017 | myelodysplastic syndrome | SymBio Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1 | NCT02543879 Background | Sep 2015 → Mar 2019 | acute myeloid leukemia, myelodysplastic syndrome, non-Hodgkin lymphoma | Forma Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT02323139 Background | Feb 2015 → Jan 2018 | myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Completed | No outcome recorded |
| Phase 1 | NCT02038777 Background | Mar 2014 → Feb 2021 | acute myeloid leukemia | Pfizer | Completed | No outcome recorded |
| Phase 1 | NCT01913951 Background | Nov 2013 → Dec 2016 | myelodysplastic syndrome | Washington University School of Medicine | Completed | No outcome recorded |
| Phase 1 | NCT01814826 Background | Apr 2013 → May 2016 | acute myeloid leukemia | Millennium Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT01110473 Background | Apr 2010 → Jun 2013 | B-cell chronic lymphocytic leukemia, acute myeloid leukemia, chronic myeloid leukemia, myelodysplastic syndrome | AbbVie | Completed | No outcome recorded |
| Phase 1 | NCT00741234 Background | Apr 2007 → Mar 2012 | cancer, hematopoietic and lymphoid cell neoplasm, myelodysplastic syndrome | S*BIO | Completed | No outcome recorded |
| Phase 1 | NCT00351975 Background | Jun 2006 → Mar 2013 | acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia with t(9;11)(p22;q23), acute myeloid leukemia, inv(16)(p13.1;q22), acute myeloid leukemia, t(16;16)(p13.1;q22) +8 | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1 | NCT00217542 Background | Jul 2005 → Jul 2008 | melanoma, renal cell carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/236 trials | ||||||
| Phase 1/2 | NCT07646821 Background | Nov 2026 → Dec 2028 expected | myeloid hemopathy | M.D. Anderson Cancer Center | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07486726 Background | Mar 2026 → Oct 2027 expected | acute myeloid leukemia | Shanghai Jiao Tong University School of Medicine | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT07028073 Background | May 2025 → May 2027 expected | acute myeloid leukemia with t(8;21)(q22;q22) translocation, acute myeloid leukemia, KIT gene mutation, acute myeloid leukemia, t(16;16)(p13.1;q22) | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06746519 Background | Dec 2024 → Dec 2025 overdue | acute myeloid leukemia | Chen Suning | Recruiting | No outcome recorded |
| Phase 1/2 | NCT06150040 Background | Sep 2024 → Feb 2025 | acute myeloid leukemia | Centre Leon Berard | Terminated | No outcome recorded |
| Phase 1/2 | NCT06387420 Background | Apr 2024 → Apr 2026 overdue | acute myeloid leukemia | Akeso | Not yet recruiting | No outcome recorded |
| Phase 1/2 | NCT03932318 Background | Mar → Dec 2023 | acute myeloid leukemia | Actinium Pharmaceuticals | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT05428969 Background | Jun 2022 → Mar 2027 expected | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Faron Pharmaceuticals Ltd | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04988555 Background | Feb 2022 → Jun 2027 expected | acute lymphoblastic leukemia, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | Sumitomo Pharma America, Inc. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04964518 Background | Jul 2021 → Jul 2024 | acute myeloid leukemia | Ascentage Pharma Group Inc. | Unknown | No outcome recorded |
| Phase 1/2 | NCT04734990 Background | Jul 2021 → Sep 2027 expected | chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04900350 Background | Jun 2021 → Sep 2025 overdue | myelodysplastic syndrome | Akeso | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04588922 Background | May 2021 → Dec 2026 expected | hematopoietic and lymphoid cell neoplasm | Sellas Life Sciences Group | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04742101 Background | Mar 2021 → Mar 2026 | acute myeloid leukemia | Servier | Completed | No outcome recorded |
| Phase 1/2 | NCT04629443 Background | Feb 2021 → Aug 2023 | acute myeloid leukemia | Servier | Completed | No outcome recorded |
| Phase 1/2 | NCT04599452 Background | Dec 2020 → Dec 2023 | acute myeloid leukemia | The Second Hospital of Shandong University | Unknown | No outcome recorded |
| Phase 1/2 | NCT04729543 Background | Oct 2020 → Dec 2024 overdue | uveal melanoma | Erasmus Medical Center | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04550442 Background | Sep 2020 → May 2026 | chronic myelomonocytic leukemia, myelodysplastic syndrome, therapy related acute myeloid leukemia and myelodysplastic syndrome | M.D. Anderson Cancer Center | Terminated | No outcome recorded |
| Phase 1/2 | NCT04493138 Background | Jul 2020 → Dec 2027 expected | chronic myelomonocytic leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT04068597 Background | Aug 2019 → Mar 2027 expected | T-cell non-Hodgkin lymphoma, acute myeloid leukemia, myelodysplastic syndrome, plasma cell myeloma | CellCentric Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT03684811 Background | Nov 2018 → May 2021 | chondrosarcoma, intrahepatic cholangiocarcinoma, malignant glioma | Forma Therapeutics, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT03614728 Background | Oct 2018 → Jan 2022 | neoplasm | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 1/2 | NCT03072043 Background | May 2017 → Nov 2019 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | H. Lee Moffitt Cancer Center and Research Institute | Completed | No outcome recorded |
| Phase 1/2 | NCT03030612 Background | Dec 2016 → Aug 2022 | acute myeloid leukemia, myelodysplastic syndrome | OncoVerity, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02835794 Background | Aug 2016 → Dec 2018 | myelodysplastic syndrome | University of Florida | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT02677922 Background | Jun 2016 → Aug 2018 overdue | acute myeloid leukemia | Celgene Corporation | Active not recruiting | No outcome recorded |
| Phase 1/2 | NCT02711137 Background | May 2016 → Feb 2019 | cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02712905 Background | May 2016 → Apr 2022 | hematopoietic and lymphoid system neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02706899 Background | Feb 2016 → Nov 2017 | myelodysplastic syndrome | Seagen Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT02587598 Background | Dec 2015 → Aug 2020 | cancer | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT02400281 Background | Sep 2015 → Jul 2020 | acute myeloid leukemia | Arog Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT02343939 Background | Jul 2015 → Sep 2018 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 1/2 | NCT02265510 Background | Sep 2014 → Feb 2019 | metastatic malignant neoplasm | Incyte Corporation | Terminated | No outcome recorded |
| Phase 1/2 | NCT01926587 Background | Aug 2013 → Dec 2020 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Traws Pharma, Inc. | Completed | No outcome recorded |
| Phase 1/2 | NCT01828346 Background | Jun 2013 → Jun 2015 | myelodysplastic syndrome | TetraLogic Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/2 | NCT01093573 Background | Jul 2009 → Sep 2016 | acute myeloid leukemia | Brenda Cooper, MD | Completed | No outcome recorded |
| Phase 253 trials | ||||||
| Phase 2 | NCT07672769 Background | Oct 2026 → Nov 2027 expected | myelodysplastic syndrome | Faron Pharmaceuticals Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07710534 Comparator | Sep 2026 → Sep 2031 expected | acute myeloid leukemia, myelodysplastic syndrome | Virginia Commonwealth University | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07463768 Background | Sep 2026 → Sep 2030 expected | acute myeloid leukemia | French Innovative Leukemia Organisation | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07642453 Background | Jun 2026 → Jun 2028 expected | acute myeloid leukemia | Hematology department of the 920th hospital | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07060001 Comparator | Apr 2026 → Dec 2028 expected | acute myeloid leukemia | The Methodist Hospital Research Institute | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT07148947 Background | Mar 2026 → Dec 2028 expected | myeloproliferative neoplasm | University of Washington | Recruiting | No outcome recorded |
| Phase 2 | NCT06770257 Comparator | Dec 2025 → Dec 2026 | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Withdrawn | No outcome recorded |
| Phase 2 | NCT06900088 Background | Apr → Oct 2025 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Institute of Hematology & Blood Diseases Hospital, China | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05766514 Comparator | Apr 2025 → Dec 2029 | acute myeloid leukemia, myelodysplastic syndrome | University of Florida | Withdrawn | No outcome recorded |
| Phase 2 | NCT06744556 Background | Jan 2025 → Dec 2027 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06783790 Background | Jan 2025 → Dec 2026 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06497062 Background | Oct 2024 → Oct 2027 expected | acute myeloid leukemia | Shanghai Jiao Tong University School of Medicine | Active not recruiting | No outcome recorded |
| Phase 2 | NCT07163793 Comparator | Oct 2024 → Oct 2026 expected | acute myeloid leukemia | Northwell Health | Recruiting | No outcome recorded |
| Phase 2 | NCT06635681 Background | Sep 2024 → Dec 2026 expected | acute myeloid leukemia | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT06532552 Background | Jul 2024 → Aug 2027 expected | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06384261 Background | Jul 2024 → Jan 2027 expected | acute myeloid leukemia | OncoVerity, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06316960 Background | Mar 2024 → Mar 2026 overdue | acute myeloid leukemia, KIT gene mutation, childhood acute myeloid leukemia, core binding factor acute myeloid leukemia | Children's Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06196203 Background | Feb 2024 → Jan 2026 overdue | myelodysplastic syndrome | Akeso | Recruiting | No outcome recorded |
| Phase 2 | NCT06220162 Background | Feb 2024 → Dec 2026 expected | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Recruiting | No outcome recorded |
| Phase 2 | NCT06014489 Background | Jan 2024 → Mar 2028 expected | acute myeloid leukemia | HOVON Foundation | Recruiting | No outcome recorded |
| Phase 2 | NCT06109064 Background | Oct 2023 → Feb 2024 | myelodysplastic syndrome | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06105658 Background | Oct 2023 → Feb 2024 | acute myeloid leukemia | Anhui Provincial Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT06858618 Background | Aug 2023 → Dec 2026 expected | — | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT06532058 Background | Aug 2023 → Feb 2025 overdue | acute myeloid leukemia | Changzhou Qianhong Bio-pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 2 | NCT05955261 Background | Jul 2023 → Dec 2026 | acute myeloid leukemia | St. Jude Children's Research Hospital | Suspended | No outcome recorded |
| Phase 2 | NCT05958719 Background | Mar 2023 → Dec 2026 expected | peripheral T-cell lymphoma, not otherwise specified | Institute of Hematology & Blood Diseases Hospital, China | Recruiting | No outcome recorded |
| Phase 2 | NCT05807347 Background | Feb 2023 → Feb 2024 | acute myeloid leukemia | Hematology department of the 920th hospital | Unknown | No outcome recorded |
| Phase 2 | NCT04878432 Background | Mar 2022 → Oct 2023 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT05029141 Background | Sep 2021 → Dec 2026 expected | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04905407 Background | Aug 2021 → Aug 2024 | acute myeloid leukemia | Syros Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04778410 Background | Jun 2021 → Mar 2024 | myeloid neoplasm | Gilead Sciences | Terminated | No outcome recorded |
| Phase 2 | NCT05025098 Background | Jun 2021 → Jun 2026 overdue | acute myeloid leukemia, myelodysplastic syndrome | University Hospital, Akershus | Recruiting | No outcome recorded |
| Phase 2 | NCT04812548 Background | May 2021 → May 2023 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04264806 Background | May 2021 → Apr 2022 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Janssen Research & Development, LLC | Withdrawn | No outcome recorded |
| Phase 2 | NCT04284787 Background | Feb 2021 → Jun 2023 overdue | therapy related acute myeloid leukemia and myelodysplastic syndrome | National Cancer Institute (NCI) | Active not recruiting | No outcome recorded |
| Phase 2 | NCT04146038 Background | Oct 2020 → Oct 2021 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Rutgers, The State University of New Jersey | Completed | No outcome recorded |
| Phase 2 | NCT04150029 Background | Sep 2020 → Oct 2024 | acute myeloid leukemia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT04023526 Background | Jul 2019 → Aug 2023 overdue | acute myeloid leukemia | OncoVerity, Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03946670 Background | Jun 2019 → Apr 2022 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT03493646 Comparator | May 2018 → Sep 2020 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Kirby Institute | Completed | No outcome recorded |
| Phase 2 | NCT02900560 Comparator | Dec 2016 → May 2021 | ovarian epithelial tumor | Translational Research in Oncology | Terminated | No outcome recorded |
| Phase 2 | NCT02472691 Background | May 2015 → Apr 2020 | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Heinrich-Heine University, Duesseldorf | Completed | No outcome recorded |
| Phase 2 | NCT02159040 Background | Sep 2014 → Jun 2015 | myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT02147873 Comparator | Jun 2014 → Jan 2016 | chronic myelomonocytic leukemia, myelodysplastic syndrome | TetraLogic Pharmaceuticals | Terminated | No outcome recorded |
| Phase 2 | NCT01993641 Background | Dec 2013 → May 2015 | myelodysplastic syndrome | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 2 | NCT01893372 Background | Oct 2013 → Jan 2019 | leukemia | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2 | NCT01873703 Background | Jun 2013 → Nov 2015 | myelodysplastic syndrome | Helsinn Healthcare SA | Completed | No outcome recorded |
| Phase 2 | NCT01617226 Comparator | Sep 2012 → Mar 2016 | acute myeloid leukemia | University of Birmingham | Completed | No outcome recorded |
| Phase 2 | NCT01556477 Comparator | Mar 2012 → Jul 2014 | acute myeloid leukemia, myelodysplastic syndrome | Nordic MDS Group | Unknown | No outcome recorded |
| Phase 2 | NCT01488565 Background | Dec 2010 → May 2014 | acute myeloid leukemia, myelodysplastic syndrome | Peter MacCallum Cancer Centre, Australia | Completed | No outcome recorded |
| Phase 2 | NCT01015352 Comparator | Feb 2009 → Mar 2014 | myelodysplastic syndrome | Groupe Francophone des Myelodysplasies | Completed | No outcome recorded |
| Phase 2 | NCT00321711 Comparator | Oct 2006 → Oct 2009 | myelodysplastic syndrome, thrombocytopenia | Amgen | Completed | No outcome recorded |
| Phase 2 | NCT00382590 Comparator | Aug 2005 → Feb 2008 | acute myeloid leukemia, myelodysplastic syndrome | M.D. Anderson Cancer Center | Completed | No outcome recorded |
| Phase 2/34 trials | ||||||
| Phase 2/3 | NCT07623187 Background | Nov 2026 → May 2031 expected | acute myeloid leukemia | Ipsen | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07581002 Background | Jul 2026 → Jun 2032 expected | acute myeloid leukemia | AbbVie | Not yet recruiting | No outcome recorded |
| Phase 2/3 | NCT07651176 Background | Mar 2026 → Dec 2029 expected | acute myeloid leukemia | First Affiliated Hospital of Zhejiang University | Enrolling by invitation | No outcome recorded |
| Phase 2/3 | NCT07255872 Background | Mar 2026 → Dec 2027 expected | acute myeloid leukemia | Sichuan Baili Pharmaceutical Co., Ltd. | Not yet recruiting | No outcome recorded |
| Phase 338 trials | ||||||
| Phase 3 | NCT07478991 Background | Mar 2026 → Apr 2030 expected | acute myeloid leukemia | PETHEMA Foundation | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT07007312 Background | Sep 2025 → Nov 2031 expected | acute myeloid leukemia | Kura Oncology, Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT07082452 Background | Sep 2025 → Sep 2030 expected | B-cell chronic lymphocytic leukemia | Gustave Roussy, Cancer Campus, Grand Paris | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT06641414 Background | Jan 2025 → Jun 2029 expected | myelodysplastic syndrome | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06647862 Background | Nov 2024 → Apr 2026 overdue | chronic myelomonocytic leukemia | ImmuneOnco Biopharmaceuticals (Shanghai) Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06389292 Background | Jun 2024 → May 2028 expected | acute myeloid leukemia | Ascentage Pharma Group Inc. | Recruiting | No outcome recorded |
| Phase 3 | NCT06387069 Comparator | Apr 2024 → Dec 2028 expected | acute myeloid leukemia | Hutchmed | Recruiting | No outcome recorded |
| Phase 3 | NCT06345365 Comparator | Jan 2024 → Dec 2026 expected | acute myeloid leukemia | Zhongnan Hospital | Recruiting | No outcome recorded |
| Phase 3 | NCT05883956 Comparator | Dec 2023 → Dec 2024 overdue | acute myeloid leukemia, chronic myelomonocytic leukemia, myelodysplastic syndrome | Otsuka Australia Pharmaceutical Pty Ltd | Active not recruiting | No outcome recorded |
| Phase 3 | NCT05876832 Comparator | Jun 2023 → Jul 2027 expected | acute myeloid leukemia, FLT3 internal tandem duplication | Shijiazhuang Yiling Pharmaceutical Co. Ltd | Not yet recruiting | No outcome recorded |
| Phase 3 | NCT05709093 Comparator | Mar 2023 → Apr 2024 | myelodysplastic syndrome | TJ Biopharma Co., Ltd. | Terminated | No outcome recorded |
| Phase 3 | NCT05586074 Comparator | Mar 2023 → Nov 2027 expected | acute myeloid leukemia | Sunshine Lake Pharma Co., Ltd. | Recruiting | No outcome recorded |
| Phase 3 | NCT05183035 Background | Oct 2022 → Feb 2027 expected | acute myeloid leukemia | PedAL BCU, LLC | Recruiting | No outcome recorded |
| Phase 3 | NCT05079230 Background | Jul 2022 → Apr 2024 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT05457361 Comparator | Mar → Dec 2022 | — | Nanfang Hospital, Southern Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04778397 Background | Jul 2021 → Mar 2024 | acute myeloid leukemia | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT04722952 Background | May 2021 → Jan 2023 | acute myeloid leukemia | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase 3 | NCT04716114 Comparator | Mar 2021 → Dec 2025 | acute myeloid leukemia | CSPC ZhongQi Pharmaceutical Technology Co., Ltd. | Unknown | No outcome recorded |
| Phase 3 | NCT05264883 Comparator | Mar 2021 → Jun 2023 | acute myeloid leukemia | The First Affiliated Hospital with Nanjing Medical University | Unknown | No outcome recorded |
| Phase 3 | NCT04797780 Background | Feb 2021 → Nov 2024 | myelodysplastic syndrome | Syros Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT04229979 Comparator | Feb 2021 → Dec 2025 overdue | acute myeloid leukemia | Sellas Life Sciences Group | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04401748 Background | Sep 2020 → Jul 2027 expected | myelodysplastic syndrome | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT04313881 Background | Sep 2020 → Sep 2023 | myelodysplastic syndrome | Gilead Sciences | Terminated | No outcome recorded |
| Phase 3 | NCT04266301 Background | Jun 2020 → Oct 2024 | chronic myelomonocytic leukemia, myelodysplastic syndrome | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 3 | NCT03765541 Background | Jan 2020 → May 2024 | acute myeloid leukemia | University Hospital, Toulouse | Terminated | No outcome recorded |
| Phase 3 | NCT03926624 Comparator | Nov 2019 → Jan 2026 | acute myeloid leukemia | Delta-Fly Pharma, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT03978364 Comparator | Jun 2019 → Jun 2022 | acute myeloid leukemia | Shandong Provincial Hospital | Unknown | No outcome recorded |
| Phase 3 | NCT03416179 Background | Apr 2018 → Jun 2020 | acute myeloid leukemia | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT03173248 Background | Jun 2017 → Mar 2021 overdue | acute myeloid leukemia | Servier | Active not recruiting | No outcome recorded |
| Phase 3 | NCT03151408 Background | Jun 2017 → Aug 2020 | acute myeloid leukemia | Helsinn Healthcare SA | Terminated | No outcome recorded |
| Phase 3 | NCT02920008 Comparator | Mar 2017 → Jan 2020 | acute myeloid leukemia | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02993523 Comparator | Feb 2017 → Dec 2021 overdue | acute myeloid leukemia | AbbVie | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02665065 Comparator | Jun 2016 → Jun 2022 overdue | acute myeloid leukemia | Actinium Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 3 | NCT02577406 Comparator | Dec 2015 → Mar 2020 | acute myeloid leukemia | Celgene Corporation | Completed | No outcome recorded |
| Phase 3 | NCT02562443 Background | Dec 2015 → Jul 2020 | myelodysplastic syndrome with excess blasts | Traws Pharma, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT02421939 Comparator | Oct 2015 → Sep 2018 | acute myeloid leukemia | Astellas Pharma Global Development, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02348489 Comparator | Mar 2015 → May 2018 | acute myeloid leukemia | Astex Pharmaceuticals, Inc. | Completed | No outcome recorded |
| Phase 3 | NCT02158936 Background | Jun 2014 → Apr 2016 | thrombocytopenia | Novartis Pharmaceuticals | Terminated | No outcome recorded |
| Phase 43 trials | ||||||
| Phase 4 | NCT07046182 Background | Oct 2023 → May 2028 expected | angioimmunoblastic T-cell lymphoma | Zhengzhou University | Active not recruiting | No outcome recorded |
| Phase 4 | NCT03873311 Comparator | Sep 2019 → Dec 2022 | myeloid leukemia | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT01011283 Comparator | Nov 2009 → Jan 2011 | myelodysplastic syndrome | Eisai Inc. | Terminated | No outcome recorded |
| Phase not applicable3 trials | ||||||
| — | NCT06030089 Background | Feb → Sep 2024 | acute myeloid leukemia | Centre Hospitalier Universitaire de Nice | Completed | No outcome recorded |
| — | NCT06256627 Comparator | Jul 2023 → Mar 2025 overdue | acute myeloid leukemia | Henan Cancer Hospital | Recruiting | No outcome recorded |
| — | NCT05797948 Background | Jul 2022 → Jun 2024 | B-cell non-Hodgkin lymphoma | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
| Phase not stated2 trials | ||||||
| — | NCT04484363 Background | — | myelodysplastic syndrome | Takeda | No longer available | No outcome recorded |
| — | NCT03723135 Background | — | acute myeloid leukemia | Celgene Corporation | Approved for marketing | No outcome recorded |
Press releases naming this drug 11 releases
| Date | Issuer | Release |
|---|---|---|
| 2023-12-10 | AbbVie | ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH abbvie.com ↗ |
| 2023-07-21 | Gilead Sciences | Gilead To Discontinue Phase 3 ENHANCE Study of Magrolimab Plus Azacitidine in Higher-Risk MDS gilead.com ↗ |
| 2022-12-10 | AbbVie | ImmunoGen Presents Findings from Expansion Cohorts in Phase 1b/2 Study of Pivekimab Sunirine with Vidaza® and Venclexta® in Acute Myeloid Leukemia at ASH abbvie.com ↗ |
| 2022-01-25 | Gilead Sciences | Gilead Announces Partial Clinical Hold for Studies Evaluating Magrolimab in Combination With Azacitidine gilead.com ↗ |
| 2021-12-12 | AbbVie | ImmunoGen Presents Initial Findings From the Phase 1b/2 Study of IMGN632 in Combination With Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH abbvie.com ↗ |
| 2021-11-04 | AbbVie | ImmunoGen to Present Initial Data Combining IMGN632 with Vidaza® and Venclexta® in Relapsed/Refractory Acute Myeloid Leukemia at ASH abbvie.com ↗ |
| 2021-07-21 | Roche Global Development | FDA grants Breakthrough Therapy Designation for Venclexta in combination with azacitidine for the treatment of patients with myelodysplastic syndromes roche.com ↗ |
| 2020-06-13 | AbbVie | VENCLEXTA®/VENCLYXTO® (venetoclax) Plus Azacitidine Demonstrates Statistically Significant Overall Survival Benefit and Improved Remission Rates in Treatment-Naïve Acute Myeloid Leukemia Patients abbvie.com ↗ |
| 2020-05-29 | Takeda | Takeda Announces Compelling Data from the Phase 2 Trial of Pevonedistat Plus Azacitidine in Patients with Higher-Risk MDS takeda.com ↗ |
| 2020-05-29 | Gilead Sciences | Investigational Magrolimab in Combination With Azacitidine Demonstrates Durable Activity in Previously-Untreated Myelodysplastic Syndrome and Acute Myeloid Leukemia gilead.com ↗ |
| 2020-03-23 | AbbVie | AbbVie Announces Positive Topline Results from Phase 3 Trial of VENCLEXTA® (venetoclax) in Combination with Azacitidine in Patients with Acute Myeloid Leukemia (AML) abbvie.com ↗ |
Evidence & citations 42 cited values
Every value below carries the sentence it was read from. 829 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | azacitidine | “Eligible subjects with NPM1 MRD positivity will receive oral arsenic trioxide (oral-As2O3) (Arsenol ®) (5-10mg per day, from days 1-7 per cycle), ascorbic acid (1g per day,...” NCT04689815 ↗693“This is a multicenter, nonrandomized, open-label phase 2 study (with a safety run-in phase) of azacitidine (AZA) 75 mg/m2 given IV or SQ on days 1-7 every 28 days in...” NCT02845297 ↗ “Participants will receive standard low-intensity therapy (LIT) regimens for newly diagnosed AML, which may include venetoclax combined with either azacitidine, decitabine, or...” NCT07014462 ↗ “A Single-arm, Single-center Clinical Trial Evaluating the Efficacy and Safety of a Regimen Combining Chidamide With Venetoclax, Azacitidine, and Homoharringtonine in the...” NCT07643636 ↗ “Each 28-day cycle is comprised of Pevonedistat at 20 mg/m2 IV infusion over 1 hour on days 1, 3 and 5 and Azacitidine at 25 mg/m2 IV infusion over 30 minutes on days 1, 2, 3,...” NCT03709576 ↗ “Drugs used in chemotherapy, such as azacitidine, work in different ways to stop the growth of abnormal cells, either by killing the cells or by stopping them from dividing.” NCT00398047 ↗ “Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles.” NCT05782127 ↗ “This phase 2 study evaluated oral azacitidine (CC-486) plus cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) as initial treatment for PTCL.” PMID 36796016 ↗ May 2023 “I. To document the toxicities, and reversibility of toxicities, of this regimen of 5-azacytidine (azacitidine) and erlotinib (erlotinib hydrochloride).” NCT00996515 ↗ “Azacitidine 75 mg/m2 Subcutaneous (SC) or IV Daily with a continuous 7-day scheme or on a 5-on/2-off [weekend]/2-on schedule (5-0-2) in 28-day cycle” NCT07082452 ↗ “Drug: Azacitidine Tablets or capsules for oral administration and powder for reconstitution to aqueous suspension for subcutaneous administration” NCT04608110 ↗ “Azacitidine +Selinexor ± venetoclax were administered (Selinexor: 60mg/ week, qw*4 weeks; azacitidine: 100mg/m2*d1-d7; venetoclax, 100mg d1-14).” NCT07632170 ↗ “Azacitidine (5-azacytidine) is a nucleoside metabolic inhibitor that has been US Food and Drug Administration-approved for several MDS subtypes.” NCT04609826 ↗ “Azacitidine (100 mg/m2) is given once daily following administration of venetoclax for 5 days of every cycle, starting on Day 1 of each cycle.” NCT05025098 ↗ “Venetoclax and azacitidine are front-line therapy for such patients, and ADI-PEG 20 will be added to this regimen in a phase IA/B study.” NCT05001828 ↗ “the XAB regimen: a chemotherapy-free or low-dose chemotherapy regimen containing selinexor (X), azacitidine (A), and venetoclax (B)” NCT07236931 ↗ “CD47 monoclonal antibody combined with azacitidine is used for the treatment of patients with recurrent AML after transplantation” NCT05266274 ↗ “Venetoclax 100mg day 1, 200mg day 2, 400mg days 3-28 Azacitidine 75mg/m² days 1-7 Avapritinib orally on days 8-21 (28-day cycle)” NCT07028073 ↗ “The choice of HMA agent (e.g. azacitidine or decitabine) will be the HMA the patient has received prior to enrollment on study.” NCT01893372 ↗ “maintenance therapy with Selinexor combined with Azacitidine in patients with high-risk myeloid neoplasms after transplantation” NCT06900088 ↗ “An oral formulation of azacitidine currently being developed for the treatment of hematological and solid malignancies.” NCT05287568 ↗ “Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)” NCT05833438 ↗ “Clinical Trial Protocol for the Combined Use of Azacitidine, Venetoclax, and Granulocyte Colony-Stimulating Factor” NCT06536010 ↗ “Azacitidine: 75 mg/m², intravenously (iv) or subcutaneously (sc), once daily on Days 1-7 of each 28-day cycle.” NCT07259707 ↗ “Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.” NCT02562443 ↗ “* Azacitidine: Azacitidine Injection 75 mg/m2, QD, subcutaneous or IV for 7 consecutive days (Days 1-7).” NCT06387069 ↗ “Subcutaneous injection of azacitidine at 32 mg/m² per day for 5 consecutive days, with a 28-day cycle” NCT06612944 ↗ “venetoclax and Azacitidine combined with homoharringtonine (VAH) bridging allogeneic transplantation” NCT07091006 ↗ “Sintilimab (IBI308) in Combination With Chidamide and Azacitidine in Refractory or Relapsed PTCL” NCT04052659 ↗ “Participants on azacitidine will receive 75 mg/m\^2 daily by SC or IV injection for 7 days.” NCT05876832 ↗ “Decitabine is being administered i.v. Azacitidine is being administered i.v or s.c.” NCT03946670 ↗ “Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).” NCT01453140 ↗ “Azacitidine: 75 mg/m2 per day by subcutaneous injection from Day 1 to Day 7;” NCT07517510 ↗ “combined with azacitidine (AZA) at a dose of 75mg/m2 per day for 7 days” NCT04424147 ↗ “eprenetapopt combined with azacitidine as maintenance therapy after HCT” PMID 35816664 ↗ Jul 2022 “5-Azacitidine (Azacitidine) is a nucleoside analogue chemotherapy drug” NCT07404332 ↗ “Low intensity: low dose cytarabine (LDAC), decitabine, or azacitidine.” NCT02920008 ↗ “AZA: Azacitidine 75 mg/m² per day, subcutaneous injection, days 1-7.” NCT07425782 ↗ “Azacitidine 100 mg D1-D5, subcutaneous injection for total 3 cycles.” NCT07493330 ↗ “5-Azacitidine(5-AZA) is the most promising drug for treatment MDSs.” NCT00897130 ↗ “Azacitidine (alternative to decitabine) Injectable 75 mg/m² per day” NCT07451912 ↗ “Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.” NCT06810791 ↗ “Azacitidine: 75 mg/m² subcutaneously once daily on days -10 to -6.” NCT07583888 ↗ “SHR2554 350 mg BID and azacitidine 75 mg/m² daily on days -9 to -3” NCT07575412 ↗ “SHR2554 350 mg BID and azacitidine 75 mg/m² daily on days -9 to -3” NCT07562568 ↗ “azacitidine 75 mg/m2 for 7 days or decitabine 20mg/m2 for 5 days” NCT01902329 ↗ “Drug: Azacitidine 75 mg/m2 subcutaneously once daily on days 1-7” NCT05807347 ↗ “Azacitidine combined with CHOP regimen every 3 weeks as below:” NCT05230680 ↗ “Azacitidine 75mg/m2/d schedule determined by treatment phases” NCT06561880 ↗ “Azacitidine (A): 50 mg/m², subcutaneous injection, Days 1-5” NCT07521124 ↗ “Venetoclax+hypomethylating agent (decitabine, azacitidine)” NCT06713837 ↗ “azacitidine 75 mg/m2 subcutaneously once daily on days 1-7” NCT05901974 ↗ “Azacitidine 75mg·m-2·d-1, d1-d7, subcutaneous injection;” NCT05584761 ↗ “CB-839 in combination with standard dose azacitidine” NCT02071927 ↗ “Subcutaneous Azacitidine 75 mg/m2/day, days 1 to 7.” NCT02319135 ↗ “Azacitidine:75mg/m2 Subcutaneous daily for 7 days” NCT06532552 ↗ “azacitidine 100mg subcutaneously on days 1-5” NCT07000617 ↗ “Azacitidine 75mg/m², IV drip, Day 1 to Day 7” NCT07028086 ↗ “Azacitidine (not allowed as a single agent)” NCT02665065 ↗ “Azacitidine 75 mg/m² SC daily on Days 1-7” NCT07172204 ↗ “Combination of Azacitidine and Venetoclax” NCT05768711 ↗ “Azacitidine (5-Azacytidine, Ladakamycin)” NCT06536959 ↗ “Azacitidine, 75 mg/m2/d,SC, on days 1-7.” NCT04541277 ↗ “Azacitidine (5-Azacytidine, Ladakamycin)” NCT05362942 ↗ “cytarabine OR azacitidine OR decitabine” NCT03236857 ↗ “Azacitidine 100mg, once daily, days 1-7” NCT06737523 ↗ “75 mg/m\^2 azacitidine given IV or SC” NCT02348489 ↗ “Azacitidine and Vorinostat: Days 1-5” NCT05317403 ↗ “Axitinib, Azacitidine, Bendamustine” NCT02788201 ↗ “Azacitidine (100mg, D1-3/5 \[SCA\])” NCT07542912 ↗ “Azacitidine: 75 mg/m² on Days 1-7.” NCT07047183 ↗ “Axitinib Azacitidine Bexarotene” NCT02551718 ↗ “APG2575 ramp up + Azacitidine” NCT04964518 ↗ “Azacitidine 75mg/m2 d5-11” NCT04599452 ↗ “Azacitidine 75mg/m2 d5-11” NCT04599426 ↗ “Other Name: Azacitidine” NCT05061147 ↗ “Drug: Azacitidine” NCT04172844 ↗ “Azacitidine” NCT05175508 ↗ “Azacitidine” NCT05188326 ↗ |
| Known as | 5' Azacytidine (AZA) | “5' Azacytidine (AZA)” NCT04729543 ↗ |
| Known as | 5'-azacitadine | “5'-azacitadine will be given at a low dose of 32mg/m2 S.C for 5 days every 28 days (a cycle).” NCT01995578 ↗ |
| Known as | 5-aza | “participants with recurrent and/or metastatic (R/M) HNSCC were treated with low-dose 5-azacytidine (5-aza) daily for either 5 or 10 days in combination with durvalumab and...” PMID 40091844 ↗ Mar 20259“The BCL2 inhibitor venetoclax (VEN) in combination with azacitidine (5-AZA) is currently transforming acute myeloid leukemia (AML) therapy.” PMID 36892565 ↗ Jun 2023 “the deoxyribonucleic acid (DNA) methyltransferase inhibitor, 5-azacitidine (5-AZA)” NCT01207726 ↗ “5-Azacytidine (5-AZA) is a chemotherapy, and nivolumab is an immunotherapy.” NCT05317000 ↗ “5-Azacytidine (5-AZA) and Trastuzumab Infusions Into the Fourth Ventricle” NCT04958486 ↗ “5-Azacitidine (5 AZA) in subjects with myelodysplastic syndrome (MDS)” NCT01828346 ↗ “5-Azacitidine(5-AZA) is the most promising drug for treatment MDSs.” NCT00897130 ↗ “5-azacytidine (5-aza) maintenance therapy after transplant” NCT02204020 ↗ “5-Azacytidine (5-AZA) group 1” NCT03572530 ↗ “Drug: 5-Azacytidine (5-aza)” NCT00326170 ↗ |
| Known as | 5-azacitidine | “To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment...” PMID 24583822 ↗ Feb 201424“The purpose of this study is to learn if 5'-Azacitidine will help to lower the risk of the disease coming back after a stem cell transplant in patients with MDS and AML.” NCT01995578 ↗ “Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)” NCT00422890 ↗ “Demethylation drugs, such as 5-azacitidine (AZA) and 5-aza-2-deoxycytidine (decitabine), can inhibit DNA methyltransferase” NCT03978364 ↗ “CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 8 cycles.” NCT04639843 ↗ “the deoxyribonucleic acid (DNA) methyltransferase inhibitor, 5-azacitidine (5-AZA)” NCT01207726 ↗ “5-Azacitidine (Azacitidine) is a nucleoside analogue chemotherapy drug” NCT07404332 ↗ “5-Azacitidine(5-AZA) is the most promising drug for treatment MDSs.” NCT00897130 ↗ |
| Known as | 5-Azacytidin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00422890 ↗ |
| Known as | 5-azacytidine | “The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗40“participants with recurrent and/or metastatic (R/M) HNSCC were treated with low-dose 5-azacytidine (5-aza) daily for either 5 or 10 days in combination with durvalumab and...” PMID 40091844 ↗ Mar 2025 “Drug2: Azacitidine (5-azacytidine) is a cytidine nucleoside analogue that selectively inhibits DeoxyriboNucleic Acid methyltransferases at low doses, resulting in gene promoter...” NCT05426798 ↗ “Azacitidine (5-azacytidine) is a nucleoside metabolic inhibitor that has been US Food and Drug Administration-approved for several MDS subtypes.” NCT04609826 ↗ “5-azacytidine can increase fetal hemoglobin levels, but this drug can damage DNA, which in turn can increase the risk of cancer.” NCT00005934 ↗ “A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML” NCT01861002 ↗ “5-Azacytidine is designed to activate ("turn on") certain genes in cancer cells whose job is to fight tumors.” NCT01254890 ↗ “5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®)” NCT00339196 ↗ “5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®)” NCT00339196 ↗ “The hypomethylating agent azacitidine (also known as 5-azacytidine or Vidaza®).” NCT02750995 ↗ “the combination of 5-Aza-Cytidine + Thalidomide in hrMDS patients.” NCT00704704 ↗ “5-azacytidine, 75 mg/m² sub cut QD started from day5 to day10” NCT07522801 ↗ “Days 1-5: 5-Azacytidine 40 mg/m\^2 daily” NCT02124174 ↗ “5-azacytidine (AZA)” NCT03612739 ↗ |
| Known as | 5-AZC | “5-AZC” NCT01168219 ↗ |
| Known as | 5AC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01305499 ↗ |
| Known as | aza | “This study is a prospective, single-center, single-arm clinical study, which plans to enroll 40 patients with high-risk myelodysplastic syndrome (MDS) to be given azacitidine...” NCT06279338 ↗76“Herein, we present the phase 1a dose escalation data of IO-202 as monotherapy and in combination with azacitidine (AZA) in patients with relapsed/refractory (R/R) acute myeloid...” PMID 40919482 ↗ Jun 2025 “In this phase 1 study, azacitidine (AZA) was given before high-dose cytarabine (HiDAC) and mitoxantrone (mito) based on the hypothesis that epigenetic priming with a...” PMID 32074275 ↗ Feb 2020 “This research is being done to study the efficacy and safety of unrelated umbilical cord blood stem cell microtransplantation combined with azacitidine(AZA) based treatment for...” NCT05584761 ↗ “This is a prospective, single-arm, multicenter, phase II clinical trial to evaluate the efficacy and safety of AZA（azacytidine）combined with the R-GemOx (rituximab, gemcitabine...” NCT06778902 ↗ “This single arm, prospective study on the feasibility of a bridging treatment with low-dose azacitidine (AZA) in combination with short term CAG derived regimen prior to...” NCT04216355 ↗ “This is a multicenter, nonrandomized, open-label phase 2 study (with a safety run-in phase) of azacitidine (AZA) 75 mg/m2 given IV or SQ on days 1-7 every 28 days in...” NCT02845297 ↗ “Based on the efficacy data of venetoclax (VEN)-based treatment in NPM1mut AML older patients, we retrospectively analysed the off-label combination of VEN plus azacitidine...” PMID 37226312 ↗ May 2023 “This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA)...” NCT07581002 ↗ “To investigate its mechanism of action, we performed integrative expression and methylation analysis of 63 cancer cell lines (breast, colorectal, and ovarian) after treatment...” PMID 24583822 ↗ Feb 2014 “a novel biomodulatory treatment regimen consisting of low-dose azacitidine (AZA) in combination with PPARγ agonist pioglitazone (PGZ) and all-trans retinoic acid (ATRA) induced...” PMID 30542286 ↗ Nov 2018 “decitabine or azacitidin (AZA), producing complete remission (CR) plus CR with incomplete hematologic recovery (CRi) rates of 74% and 66.7%, respectively, in previously...” NCT04824924 ↗ “This is a single arm study to evaluate the safety and efficiency of azacitidine (AZA) combination with venetoclax and ATRA in Patients With Newly diagnosed acute myeloid leukemia.” NCT05654194 ↗ “• Azacitidine (Aza): The dosage is 75 mg/m² per day, administered via subcutaneous injection (Subcutaneous injection, SC) or intravenous injection (Intravenous, IV).” NCT07007949 ↗ “Azacitidine (AZA): AZA is administered by subcutaneous injection once a day at a dose of 75 mg/m2 on D1 to D7 of each treatment cycle in 28-day treatment cycles.” NCT05709093 ↗ “Hypomethylating agents (HMA) like azacytidine (AZA) and decitabine (DEC), have been shown to improve survival or delay disease progression in high-risk MDS.” NCT06004765 ↗ “protein synthesis inhibitor omacetaxine mepesuccinate (oma) with the hypomethylating agent (HMA) azacitidine (aza) for patients with untreated MDS-EB.” PMID 41140451 ↗ Oct 2025 “Azacitidine (AZA): 75mg/m2 subcutaneous at two different sites daily (d1 to d7);(Choose decitabine or azacitidine according to the patient's wishes)” NCT05264883 ↗ “Part 1 will be the Dose Confirmation portion to determine recommended Phase 3 dose (RPTD) of venetoclax in combination with azacitidine (AZA).” NCT04102020 ↗ “A subset of opt-in participants will receive a single dose (75mg/m²) of 5-Azacitidine (AZA), an FDA-approved drug for pediatric oncology.” NCT07434492 ↗ “The auxiliary treatment is oral azacitidine. Oral AZA 300 mg will be given once-daily for 14 days of repeated 28-day treatment cycles.” NCT07463768 ↗ “Platzbecker et al. applied azacytidine (AZA) monotherapy to AML patients with continuous MRD positive after combined chemotherapy.” NCT05361057 ↗ “Azacitidine (AZA) 25 mg/m2 (days 1-5) was added starting with cycle 4 and could be subsequently increased to 75 mg/m2 (days 1-5).” PMID 30185431 ↗ Sep 2018 “We performed a phase 1b study of pevonedistat (PEV) with azacitidine (AZA) based on synergistic activity seen preclinically.” PMID 29348128 ↗ Jan 2018 “Demethylation drugs, such as 5-azacitidine (AZA) and 5-aza-2-deoxycytidine (decitabine), can inhibit DNA methyltransferase” NCT03978364 ↗ “Azacitidine (AZA) 75 mg/m2, d1-5 of each 28 day cycle (SC) in combination with Venetoclax (VEN): 400 mg daily (orally)” NCT05833438 ↗ “A Phase I Study of 5-Azacytidine in Combination With Chemotherapy for Children With Relapsed or Refractory ALL or AML” NCT01861002 ↗ “5-azacytidine (azacitidine; AZA) combined with venetoclax (VEN) as maintenance therapy after achieving remission.” NCT04062266 ↗ “Azacitidine (AZA) is to be administered every 28 days beginning day +56 to 100 posttransplant for one year” NCT01541280 ↗ “Patients will receive best supportive care (BSC): azacitidine (AZA) and/or decitabine (DAC) are permitted.” NCT02562443 ↗ “For all the participants who are eligible for this trial, Azacitidine (AZA): 75 mg/m² per day on Days 1-7.” NCT07548710 ↗ “Azacitidine (AZA) has been used to treat patients with tMN but current data are retrospective.” PMID 26577691 ↗ Nov 2015 “Azacitidine (AZA) 75 milligrams per meters squared (mg/m2) taken per institutional practice” NCT07710534 ↗ “A Phase 1b Study of Lonitoclax + Azacitidine (Aza) in Acute Myeloid Leukemia (AML) Patients” NCT07303660 ↗ “Venetoclax (VEN)+Azacytidine (AZA) Followed by Modified BUCY Conditioning Regimen” NCT05809167 ↗ “DNA demethylating agents such as decitabine (DAC) and azacytidine (AZA).” NCT04648826 ↗ “combined with azacitidine (AZA) at a dose of 75mg/m2 per day for 7 days” NCT04424147 ↗ “AZA: Azacitidine 75 mg/m² per day, subcutaneous injection, days 1-7.” NCT07425782 ↗ “Azacitidine (AZA) is given 75 mg/m2 subcutaneously from day 1 to 7.” NCT06810791 ↗ “Arm A: Bleximenib and Venetoclax (VEN) + Azacitidine (AZA)” NCT06852222 ↗ “Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd)” NCT05431257 ↗ “azacitidine (Aza) administered sequentially with” PMID 22816680 ↗ Jul 2012 “standard dose of azacytidine (AZA) in Phase 1” NCT03030612 ↗ “Arm B: JNJ-74856665 + Azacitidine (AZA)” NCT04609826 ↗ “this drug, called 5-Azacytidine (AZA).” NCT06377085 ↗ “Azacitidine (AZA) or Decitabine (DAC)” NCT07238686 ↗ “Azacitidine (AZA) with Ruxolitinib” NCT05817955 ↗ “Azacitidine (AZA) Days 1 - 5” NCT06686108 ↗ “Drug: Azacitidine (AZA)” NCT07407660 ↗ “Drug: Azacitidine (AZA)” NCT05275439 ↗ “Drug: Azacitidine (AZA)” NCT07007312 ↗ “Drug: Azacitidine (AZA)” NCT07159620 ↗ “Drug: Azacitidine (AZA)” NCT07425808 ↗ “Drug: Azacitidine (AZA)” NCT07078591 ↗ “5-azacytidine (AZA)” NCT03612739 ↗ “Azacitidine (AZA)” NCT07471841 ↗ “azacitidine (AZA)” NCT06641414 ↗ “Azacitidine (AZA)” NCT06696183 ↗ “Azacitidine (AZA)” NCT04988555 ↗ “Azacitidine (AZA)” NCT06754540 ↗ “Azacitidine (AZA)” NCT04581512 ↗ “azacitidine (AZA)” NCT03047993 ↗ “Azacitidine (Aza)” NCT04778410 ↗ “Azacitidine (AZA)” NCT06903702 ↗ “Azacitidine (AZA)” NCT07372352 ↗ “Azacitidine (AZA)” NCT01460498 ↗ “Azacitidine (AZA)” NCT07573670 ↗ “Azacitidine (AZA)” NCT05453903 ↗ “Azacitidine (AZA)” NCT07598578 ↗ “Azacitidine (AZA)” NCT07646821 ↗ “Azacitidine (AZA)” NCT06668558 ↗ “Azacitidine (AZA)” NCT07148180 ↗ “Azacitidine (AZA)” NCT06927232 ↗ “Azacitadine (AZA)” NCT06651229 ↗ “Azacitidine (AZA)” NCT07635485 ↗ “Azacitidine (AZA)” NCT06896110 ↗ “Azacitidine (AZA)” NCT07060001 ↗ |
| Known as | azacitadine | “Azacitadine 100mg/day ivgtt D-7 to -1 if with TET2/KMT2D gene mutation.” NCT04480099 ↗ |
| Known as | Azacitadine (AZA) | “Drug: Azacitadine (AZA)” NCT06561880 ↗ |
| Known as | Azacitidene | “This study will assess the adverse events and changes in the disease activity when Pivekimab Sunirine (PVEK) is given in combination with Venetoclax (VEN) and Azacitidene (AZA)...” NCT07581002 ↗ |
| Known as | azacitidin | “decitabine or azacitidin (AZA), producing complete remission (CR) plus CR with incomplete hematologic recovery (CRi) rates of 74% and 66.7%, respectively, in previously...” NCT04824924 ↗ |
| Known as | Azacitidina | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | Azacitidine (5-Azacytidine, Ladakamycin) | “Azacitidine (5-Azacytidine, Ladakamycin)” NCT05362942 ↗ |
| Known as | Azacitidine (AZA) | “Azacitidine (AZA)” NCT05061147 ↗ |
| Known as | Azacitidine (Vidaza) | “Azacitidine (Vidaza)” NCT01748240 ↗ |
| Known as | Azacitidine = Vidaza (Celgene) | “Azacitidine = Vidaza® (Celgene)” NCT01324960 ↗ |
| Known as | Azacitidine accord | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | Azacitidine betapharm | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | Azacitidine celgene | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | Azacitidine kabi | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | Azacitidine mylan | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | azacytidine | “The goal of this clinical research study is to find the highest tolerable dose of Azacytidine (5-azacytidine) combined with cytosine arabinoside (ara-C) for the treatment of...” NCT00569010 ↗46“Low-dose cytarabine (LoDAC); azacytidine; homoharringtonine (HHT), cytarabine and aclarubicin (HAA) or fludarabine, cytarabine and granulocyte colony-stimulating factor (FLAG)” NCT04716114 ↗ “A Study of ARGX-110 in Combination With Azacytidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) or High Risk Myelodysplatic Syndrome (MDS)” NCT03030612 ↗ “Hypomethylating agents (HMA) like azacytidine (AZA) and decitabine (DEC), have been shown to improve survival or delay disease progression in high-risk MDS.” NCT06004765 ↗ “VA regimen: azacytidine, 75mg/m2, subcutaneously, on days 1-7; venetoclax, orally, once a day, 100mg, d1; 200mg, d2; 400mg, days 3-28.” NCT05939180 ↗ “Platzbecker et al. applied azacytidine (AZA) monotherapy to AML patients with continuous MRD positive after combined chemotherapy.” NCT05361057 ↗ “Azacytidine is a DNA methylation transferase inhibitor that can re-express tumor suppressor genes in leukemia cells.” NCT05823714 ↗ “Azacytidine is a DNA methylation transferase inhibitor that can re-express tumor suppressor genes in leukemia cells.” NCT05809167 ↗ “All patients receive azacytidine and venetoclax as leukemia debulking treatment” NCT04904237 ↗ “comparing azacytidine (AZA) with fludarabine plus low-dose cytarabine (FLUGA).” PMID 34070172 ↗ May 2021 “azacytidine 75mg/m2 intravenously daily for 7 days (d3-d9)” NCT05029141 ↗ “Azacytidine 75mg/(m2.d) by IV on days 1-7 of every cycle.” NCT04722952 ↗ “Standard azacytidine treatment (AZA; D1-D7, 75mg/m2 qd)” NCT05431257 ↗ “1. Azacytidine (75 mg/m2/day, days 1 to 7).” NCT07512700 ↗ “5' Azacytidine (AZA)” NCT04729543 ↗ |
| Known as | AZC | “Azacitidine (AZC)” NCT01812252 ↗1“Azacitidine (AZC)” NCT06773208 ↗ |
| Known as | BMS-986345 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05065866 ↗ |
| Known as | CC-486 | “VIALE-M is a randomized, double-blind, two-arm study to evaluate the safety and efficacy of venetoclax in combination with oral azacitidine (CC-486) as maintenance therapy in...” PMID 35852098 ↗ Jul 202226“The purpose of this study is to evaluate the standard treatment, azacitidine (Vidaza) given as an injection under the skin compared to the same medication (called CC-486) taken...” NCT03493646 ↗ “Onureg (CC-486, oral azacitidine) will be administered orally at 200 or 300 mg once daily for 7 or 14 consecutive days, beginning on Day 1 of repeated 28-day cycles.” NCT05782127 ↗ “a regimen combining oral azacitidine (CC-486) and nivolumab in patients with Hodgkin lymphoma (HL) refractory to PD1/PD-L1 therapy.” NCT05162976 ↗ “CC-486 (5-azacitidine) with a dose of 300mg oral intake daily will be given on day 1 to day 10 for 6 cycles.” NCT04447027 ↗ “Oral Azacitidine (CC-486) Epigenetic Priming and Maintenance for Adult Acute Myeloid Leukemia (AML) Patients” NCT06180863 ↗ “with oral azacitidine (CC-486)-CHO(E)P vs CHO(E)P in previously untreated peripheral T-cell lymphomas” NCT04803201 ↗ “Oral azacitidine (CC-486) 200 mg tablet” NCT04173533 ↗ |
| Known as | Ladakamycin | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | NSC-102816 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | Onureg | “Study Evaluating the Efficacy and Safety of the Addition of Ivosidenib to Oral Azacitidine (Onureg®) in Patients Over 55 With Acute Myeloid Leukemia (AML) and IDH1 Mutation, in...” NCT07463768 ↗ |
| Known as | Oral Azacitidine | “The purpose of the study is to determine the maximal tolerated dose and schedule of CC-486, known as oral azacitidine, in patients with AML or MDS after allogeneic hematopoetic...” NCT01835587 ↗2“Oral Azacitidine, 300mg PO Daily during days 1-14 of a 28 day cycle for up to 6 cycles.” NCT06370000 ↗ “Oral Azacitidine” NCT03723135 ↗ |
| Known as | Oral-AZA | “In the phase 3 QUAZAR AML-001 trial (NCT01757535) of patients with acute myeloid leukaemia (AML) in remission following intensive chemotherapy (IC) and ineligible for...” PMID 37952982 ↗ Nov 2023 |
| Known as | U-18,496 | ChEMBL registry synonym — accepted as the source's own label CHEMBL1489 ↗ |
| Known as | VIDAZA | “The purpose of this study is to determine if the addition of a drug called azacitidine (Vidaza®)when added to carboplatin and paclitaxel will change the genetic material of the...” NCT00842582 ↗20“Treatment of Imminent Haematological Relapse in Patients With AML and MDS Following Allogeneic Stem Cell Transplantation With 5-azacitidine (Vidaza®)” NCT00422890 ↗ “A Phase I/II Study of the Efficacy and Safety of an Intensified Schedule of Azacitidine (Vidaza®) in Intermediate-2 and High Risk MDS Patients” NCT01305460 ↗ “Azacitidine (VIDAZA) for Injection:100 mg per vial, subcutaneous injection will be administered for 7 days in each 28 day cycle” NCT04511975 ↗ “Study Examining the Combination of Revlimid (Lenalidomide)and Vidaza (Azacitidine) for Relapsed/Refractory CLL and SLL” NCT01241786 ↗ “azacitidine (also known as Vidaza®) was a current standard of care treatment option in the United States.” NCT02752035 ↗ “5-azacytidine (Vidaza®) + Valproic Acid (Depakine ®) Before Administration of Retinoic Acid (Vesanoid®)” NCT00339196 ↗ “Hypomethylating Agent Azacitidine (Vidaza) With the Nanoparticle Albumin Bound Paclitaxel (Abraxane)” NCT00748553 ↗ “Azacitidine (VIDAZA) (100 mg SQ daily on days 1-5 of each cycle, every 21 days)” NCT03182894 ↗ “Azacitidine (Vidaza®) will be administered similarly to group 1 exposed above.” NCT01342692 ↗ “Patients in treatment arm C will be receiving low-dose azacitidine (Vidaza).” NCT01453140 ↗ “Azacytidine (Vidaza®) Versus Fludarabine and Cytarabine” NCT02319135 ↗ “low dose Vidaza® (azacitidine)” NCT01379274 ↗ “Vidaza (azacitidine)” NCT02303782 ↗ “AZACITIDINE (VIDAZA)” NCT01067274 ↗ “Vidaza (azacitidine)” NCT01488565 ↗ “Vidaza” NCT00336063 ↗ |
| Known as | Vidaza (5-azacytidine) | “Vidaza (5-azacytidine)” NCT00996515 ↗ |
| Known as | Vidaza (azacitidine) | “Vidaza (azacitidine)” NCT01011283 ↗1“Vidaza (azacitidine)” NCT01488565 ↗ |
| Action | Inhibit | “Determine the minimal effective pharmacologic dose of azacitidine required to consistently inhibit DNA methyltransferase” NCT00004871 ↗1“DNA (cytosine-5)-methyltransferase 3A inhibitor” CHEMBL1489 ↗ |
| Modality | Small molecule | “5-azacytidine is a nucleoside analogue with hypomethylating activity” NCT00326170 ↗ |
| Route | Subcutaneous | “azacitidine subcutaneously daily” NCT00004062 ↗ |
| Target | DNMT1 | “The dose of AZA will be sequentially increased to maximize intra-tumoral DNMT1 depletion” NCT04648826 ↗ |
| Target | DNMT3A | “DNA (cytosine-5)-methyltransferase 3A inhibitor” CHEMBL1489 ↗ |